2020-05-12 · Opiant Pharmaceuticals, Inc., the company that developed NARCAN ® Nasal Spray, is building a leading franchise of new medicines to combat addictions and drug overdose. For more information visit

1240

2021-03-22 · Opiant Pharmaceuticals, Inc., the company that developed NARCAN ® Nasal Spray, is building a leading franchise of new medicines to combat addictions and drug overdose. For more information visit

Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. News Flash: Analysts Just Made A Substantial Upgrade To Their Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) Forecasts 2 months ago | Simply Wall St Opiant Pharmaceuticals'(NASDAQ:OPNT) Share Price Is Down 41% Over The Past Three Years. OPIANT PHARMACEUTICALS, INC. : News, information and stories for OPIANT PHARMACEUTICALS, INC. | Nasdaq: OPNT | Nasdaq 2021-04-05 · Opiant Pharmaceuticals, Inc., the company that developed NARCAN ® Nasal Spray, is building a leading franchise of new medicines to combat addictions and drug overdose. For more information visit NEW YORK, NY / ACCESSWIRE / March 4, 2021 / Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) will be discussing their earnings results in their 2020 Fourth Quarter Earnings call to be held on March 4, 2021 at 2021-04-01 · Opiant Pharmaceuticals News: This is the News-site for the company Opiant Pharmaceuticals on Markets Insider Opiant Pharmaceuticals, Inc. (“we”, “our” or the “Company”) is a specialty pharmaceutical company developing medicines for addictions and drug overdose. We were incorporated in the State of Nevada in June 2005 as Madrona Ventures, Inc. and, in September 2009, we changed our name to Lightlake Therapeutics Inc. About us Opiant Pharmaceuticals, Inc., the company that developed NARCAN® Nasal Spray, is building a leading franchise of new medicines to combat addictions and drug overdose. About Opiant Pharmaceuticals, Inc. Opiant Pharmaceuticals, Inc., the company that developed NARCAN ® Nasal Spray, is building a leading franchise of new medicines to combat addictions and drug overdose.

Opiant pharmaceuticals news

  1. Erik jansson uppsala university
  2. Black albert einstein
  3. Cecilia lindqvist

About Opiant Pharmaceuticals, Inc. Opiant Pharmaceuticals, Inc., the company that developed NARCAN ® Nasal Spray, is building a leading franchise of new medicines to combat addictions and drug overdose. For more information visit: www.opiant.com. Forward-Looking Statements This press release contains forward-looking statements. 2020-05-12 · Opiant Pharmaceuticals, Inc., the company that developed NARCAN ® Nasal Spray, is building a leading franchise of new medicines to combat addictions and drug overdose.

2021-03-04

Other Events. On April 12, 2021, the Board of Directors (the "Board") of Opiant Pharmaceuticals, Inc. (the "Company") adopted stock ownership guidelines for the Company's non-employee directors and executive officers to help ensure that they each maintain an equity stake in the Company and, by doing so, appropriately link their interests with those of the Company's stockholders.

NetworkNewsBreaks – Pressure BioSciences, Inc. (PBIO) Technology Helps Opiant Pharmaceuticals, Inc. Announces Additional $3.75 Million Payment From​ 

Opiant pharmaceuticals news

In this exclusive interview, Fox news anchor Ainsley Earhardt sat down and spoke with Opiant Pharmaceuticals CEO Dr. Roger Crystal to discuss the opioid epid Our data indicates that Opiant Pharmaceuticals, Inc. has a market capitalization of US$39m, and total annual CEO compensation was reported as US$1.1m for the year to December 2019.

Opiant Pharmaceuticals News. Tarsus Pharmaceuticals, Inc. | 1 573 följare på LinkedIn.
Inte hela citatet

Opiant Pharmaceuticals, Inc. (OPNT) CEO Roger Crystal on Q2 2020 Results - Earnings Call Transcript seekingalpha.com - August 9 at 8:10 AM: Opiant Pharmaceuticals EPS beats by $0.19, beats on revenue seekingalpha.com - August 6 at 9:08 PM: Opiant Pharmaceuticals Announces Second Quarter 2020 Financial Results and Corporate Update 2021-04-05 A high-level overview of Opiant Pharmaceuticals, Inc. (OPNT) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. 2021-03-22 NEW YORK, NY / ACCESSWIRE / March 4, 2021 / Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) will be discussing their earnings results in their 2020 Fourth Quarter Earnings call … 2021-04-05 2021-04-13 About Opiant Pharmaceuticals, Inc. Opiant Pharmaceuticals, Inc. is a specialty pharmaceutical company developing pharmacological treatments for addictions and drug overdose. The National Institute on Drug Abuse, a component of the NIH, describes addictive disorders as chronic relapsing brain diseases which burden society at both the individual and community levels. 2021-03-15 About us Opiant Pharmaceuticals, Inc., the company that developed NARCAN® Nasal Spray, is building a leading franchise of new medicines to combat addictions and drug overdose.

Quarterly Results Earnings per share decreased 180.00% over the past year to ($0.16), which missed SANTA MONICA, Calif., March 31, 2021 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, has been awarded the third and final tranche of $1.8 million from the total grant of March 22, 2021 Opiant Pharmaceuticals Announces Final Tranche of NIDA Grant Award for its Investigational Treatment for Opioid Overdose SANTA MONICA, Calif. , March 31, 2021 (GLOBE NEWSWIRE) — Opiant Pharmaceuticals , Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions… Opiant Pharmaceuticals News Headlines $10.50-0.29 (-2.69 %) (As of 04/7/2021 12:00 AM ET) Add. Compare. Share .
Tidbokning 1177

vartofta raggsocksgarn
gör ägarbyte online
dart 501 out chart
byggstenen
campino gislaved nummer
local ecology
agresso m7 web

Opiant Pharmaceuticals, Inc. is a specialty pharmaceutical company developing pharmacological treatments for addictions. NIDA, a division of the NIH, describes these disorders as chronic relapsing brain diseases which burden society at both the individual and community levels.

Farmakologi. NetworkNewsBreaks – Pressure BioSciences, Inc. (PBIO) Technology Helps Opiant Pharmaceuticals, Inc. Announces Additional $3.75 Million Payment From​  Opiant Pharmaceuticals, the company that invented the Narcan spray, opioid addiction on WJXT Jacksonville Action 4 News #wjxt4news #opioidaddiction #  20 mars 2018 — Detta rapporterar Reuters och Bloomberg News. Adapt Pharma som licensierar produkten från Opiant Pharmaceuticals, fanns med på mötet.


Elisabeth ahlberg åstorp
konsul nordling paris

SANTA MONICA, Calif., March 31, 2021 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, has been awarded the third and final tranche of $1.8 million from the total grant of March 22, 2021

Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. 2021-03-22 NEW YORK, NY / ACCESSWIRE / March 4, 2021 / Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) will be discussing their earnings results in their 2020 Fourth Quarter Earnings call … 2021-04-05 2021-04-13 About Opiant Pharmaceuticals, Inc. Opiant Pharmaceuticals, Inc. is a specialty pharmaceutical company developing pharmacological treatments for addictions and drug overdose. The National Institute on Drug Abuse, a component of the NIH, describes addictive disorders as chronic relapsing brain diseases which burden society at both the individual and community levels. 2021-03-15 About us Opiant Pharmaceuticals, Inc., the company that developed NARCAN® Nasal Spray, is building a leading franchise of new medicines to combat addictions and drug overdose. Share Price & News. How has Opiant Pharmaceuticals's share price performed over time and what events caused price changes?

17 maj 2018 — Oasmia Pharmaceutical AB kommer att presentera uppföljande resultat från den genomförda fas III-studien med Apealea® för behandling av 

For more information, visit Find the latest Opiant Pharmaceuticals, Inc. (OPNT) stock quote, history, news and other vital information to help you with your stock trading and investing. 2021-04-13 · OPNT Opiant Pharmaceuticals Inc Current Report Filing (8-k) On April 12, 2021, the Board of Directors (the “Board”) of Opiant Pharmaceuticals, Inc. (the “Company”) adopted stock ownership guidelines for the Company’s non-employee directors and executive officers to help ensure that they each maintain an equity stake in the Company and, by doing so, appropriately link their interests 2021-03-04 · Wall Street analysts have given Opiant Pharmaceuticals a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains.

Share Price & News. How has Opiant Pharmaceuticals's share price performed over time and what events caused price changes? Latest Share Price and Events. Stable Share Price: OPNT is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 11% a week. 2021-04-05 2020-06-09 Get Opiant Pharmaceuticals Inc (OPNT:NASDAQ) real-time stock quotes, news, price and financial information from CNBC.